Neuropharmagen® is a pharmacogenomics-based precision medicine platform especially developed for psychiatry. It helps optimize the pharmacological treatment based on the patient’s genetic profile, drug-drug interactions and lifestyle and clinico-physiological factors that influence the medication success.
Neuropharmagen® analyzes more that 60 polymorphisms in 26 genes to inform treatment decisions in psychiatry providing information for more that 60 psychoactive drugs most commonly used in disorders such as:
Moreover, Neuropharmagen® allows the physician to integrate patient non-genetic characteristics in the report to get real time drug-drug and drug-factor alerts on top of the gene-drug alerts.
Neuropharmagen® has proven clinical utility, demonstrated by randomized clinical trials that have shown statistically significant improvements on both efficacy and tolerability when compared with treatment as usual.
AB-BIOTICS SA
Av. Torre Blanca 57
ESADE Creapolis Building
Sant Cugat del Valles
08172 Spain
(+34) 935 803 876
Kaneka Americas Holding, Inc.
Probiotics Division
7979 Gateway Boulevard
Newark (California)
94560 United States
AB-BIOTICS Pte Ltd
10 Anson Road #12-14
International Plaza
Singapore 079903